These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4275939)

  • 21. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade.
    Teger-Nilsson AC; Larsson PT; Hjemdahl P; Olsson G
    Circulation; 1991 Dec; 84(6 Suppl):VI72-7. PubMed ID: 1683612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanism of inhibition of non-enzymatic fibrinolysis by a spleen factor].
    Liapina LA; Azieva LD
    Biokhimiia; 1985 Jan; 50(1):69-73. PubMed ID: 3978152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinolytic and renin activity in renal vein blood of patients with renovascular hypertension.
    Nowak A; Kokot F; Czekala Z; Dosiak J; Kuska J
    Thromb Diath Haemorrh; 1969 Feb; 21(1):12-9. PubMed ID: 4237621
    [No Abstract]   [Full Text] [Related]  

  • 24. [Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct].
    Belousov IuB; Panchenko EP; Pivovarov VA; Nemiro VK
    Kardiologiia; 1979 Aug; 19(8):87-91. PubMed ID: 491364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrinolysis in cholestatic jaundice.
    Jedrychowski A; Hillenbrand P; Ajdukiewicz AB; Parbhoo SP; Sherlock S
    Br Med J; 1973 Mar; 1(5854):640-2. PubMed ID: 4120848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depressed endogenous fibrinolytic activity in essential hypertension.
    Tsapogas MJ; Peabody RA; Wu KT; Devaraj KT; Eckert C
    J Cardiovasc Surg (Torino); 1974; 15(6):651-4. PubMed ID: 4281429
    [No Abstract]   [Full Text] [Related]  

  • 27. Fibrinolytic enhancement by stanozolol: a double blind trial.
    Davidson JF; Lochhead M; McDonald GA; McNicol GP
    Br J Haematol; 1972 May; 22(5):543-59. PubMed ID: 4555715
    [No Abstract]   [Full Text] [Related]  

  • 28. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.
    Heinrich J; Schulte H; Schönfeld R; Köhler E; Assmann G
    Thromb Haemost; 1995 Mar; 73(3):374-9. PubMed ID: 7667818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
    Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of lytic effect on fibrin of immobilized heparin in complex with plasma proteins].
    Platé NA; Valuev LI; Gumirova FKh; Maklakova IA
    Vopr Med Khim; 1982; 28(5):19-23. PubMed ID: 6217639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered endogenous fibrinolysis and biochemical factors in atherosclerosis.
    Peabody RA; Tsapogas MJ; Wu KT; Deveraj KT; Karmody AM; Eckert C
    Arch Surg; 1974 Aug; 109(2):309-13. PubMed ID: 4276947
    [No Abstract]   [Full Text] [Related]  

  • 32. [Contributory changes in variables of coagulation and fibrinolysis to the patency of coronary arteries in patients with acute myocardial infarction].
    Miyauchi T
    Fukuoka Igaku Zasshi; 1991 Nov; 82(11):537-49. PubMed ID: 1774011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of soluble fibrin monomer complexes in the course of myocardial infarction.
    Nowak A; Lipiński B; Drzewiecki J
    Br Heart J; 1972 Jun; 34(6):593-6. PubMed ID: 5040258
    [No Abstract]   [Full Text] [Related]  

  • 34. [Plasmin formation in a fibrin network].
    Kotschy M; Knapik M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(2):167-73. PubMed ID: 4106005
    [No Abstract]   [Full Text] [Related]  

  • 35. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction.
    Tataru MC; Heinrich J; Junker R; Schulte H; von Eckardstein A; Assmann G; Koehler E
    Eur Heart J; 1999 Oct; 20(20):1493-502. PubMed ID: 10493848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary artery spasms and heart disease.
    Marx JL
    Science; 1980 Jun; 208(4448):1127-30. PubMed ID: 6246580
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma fibrinogen, fibrinolytic activity and serum fibrinogen/fibrin degradation products in ischaemic heart disease.
    Dube B; Somani PN; Tripathi GK; Dube RK; Bhattacharya SK
    J Assoc Physicians India; 1985 Dec; 33(12):784-5, 787. PubMed ID: 3837002
    [No Abstract]   [Full Text] [Related]  

  • 38. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo assessment of thrombosis and fibrinolysis during acute myocardial infarction.
    Jaffe AS; Eisenberg PR; Wilner GD
    Prog Hematol; 1987; 15():71-89. PubMed ID: 3332392
    [No Abstract]   [Full Text] [Related]  

  • 40. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.